BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-03
185 industry Phase 2/3 trial readout(s) and 42 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2025-03-03 | FDA approval | approved | BEIGENE | TEVIMBRA | Approved 2025-03-03: TEVIMBRA (BLA761380 ORIG1) |
| 2025-03-05 | FDA approval | approved | ARS PHARMS OPERATION | NEFFY | Approved 2025-03-05: NEFFY (NDA214697 SUPPL1) |
| 2025-03-06 | FDA approval | approved | SCPHARMACEUTICALS | FUROSCIX FUROSCIX READYFLOW | Approved 2025-03-06: FUROSCIX; FUROSCIX READYFLOW (AUTOINJECTOR) (NDA209988 SUPPL3) |
| 2025-03-07 | FDA approval | approved | BOEHRINGER INGELHEIM | SYNJARDY | Approved 2025-03-07: SYNJARDY (NDA206111 SUPPL45) |
| 2025-03-07 | FDA approval | approved | NOVARTIS NVS | MEKINIST | Approved 2025-03-07: MEKINIST (NDA217513 SUPPL5) |
| 2025-03-07 | FDA approval | approved | NOVARTIS NVS | TAFINLAR | Approved 2025-03-07: TAFINLAR (NDA217514 SUPPL6) |
| 2025-03-07 | FDA approval | approved | NOVARTIS NVS | TAFINLAR | Approved 2025-03-07: TAFINLAR (NDA202806 SUPPL33) |
| 2025-03-07 | FDA approval | approved | CELLTRION INC | OMLYCLO | Approved 2025-03-07: OMLYCLO (BLA761399 ORIG1) |
| 2025-03-07 | FDA approval | approved | BOEHRINGER INGELHEIM | SYNJARDY XR | Approved 2025-03-07: SYNJARDY XR (NDA208658 SUPPL32) |
| 2025-03-07 | FDA approval | approved | NOVARTIS NVS | MEKINIST | Approved 2025-03-07: MEKINIST (NDA204114 SUPPL34) |
| 2025-03-10 | Complete response letter | complete response | Laurus Generics, Inc. | CRL 2025-03-10: Laurus Generics, Inc. NDA 217719 | |
| 2025-03-11 | Complete response letter | complete response | Seikagaku Corporation | injection | CRL 2025-03-11: Seikagaku Corporation BLA 761393 (injection) |
| 2025-03-12 | FDA approval | approved | ARRAY BIOPHARMA INC AD | BRAFTOVI | Approved 2025-03-12: BRAFTOVI (NDA210496 SUPPL18) |
| 2025-03-12 | FDA approval | approved | ARRAY BIOPHARMA INC AD | MEKTOVI | Approved 2025-03-12: MEKTOVI (NDA210498 SUPPL11) |
| 2025-03-13 | Complete response letter | complete response | Accord BioPharma Inc. | CRL 2025-03-13: Accord BioPharma Inc. BLA 761424 | |
| 2025-03-13 | FDA approval | approved | SCIENTURE SCNX | ARBLI | Approved 2025-03-13: ARBLI (NDA218772 ORIG1) |
| 2025-03-13 | FDA approval | approved | FRESENIUS KABI USA | EPINEPHRINE | Approved 2025-03-13: EPINEPHRINE (NDA215425 ORIG1) |
| 2025-03-13 | FDA approval | approved | IPSEN | SOHONOS | Approved 2025-03-13: SOHONOS (NDA215559 SUPPL2) |
| 2025-03-14 | FDA approval | approved | FRESENIUS KABI USA | TYENNE | Approved 2025-03-14: TYENNE (BLA761449 ORIG1) |
| 2025-03-14 | FDA approval | approved | XERIS XERS | GVOKE HYPOPEN; GVOKE KIT; GVOKE PFS; GVOKE VIALDX | Approved 2025-03-14: GVOKE HYPOPEN; GVOKE KIT; GVOKE PFS; GVOKE VIALDX (NDA212097 SUPPL12) |
| 2025-03-17 | FDA approval | approved | AMPHASTAR PHARMS INC AMPH | BAQSIMI | Approved 2025-03-17: BAQSIMI (NDA210134 SUPPL4) |
| 2025-03-17 | FDA approval | approved | PRM PHARMA | HEMICLOR | Approved 2025-03-17: HEMICLOR (NDA218647 ORIG1) |
| 2025-03-19 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2025-03-19: KEYTRUDA (BLA125514 SUPPL170) |
| 2025-03-20 | Complete response letter | complete response | Elevar Therapeutics, Inc. | ®® _ (rivoceranib) tablets | CRL 2025-03-20: Elevar Therapeutics, Inc. NDA 216586 (®® _ (rivoceranib) tablets) |
| 2025-03-20 | Complete response letter | complete response | Jiangsu Hengrui Pharmaceuticals Co., Ltd JHPCY | camrelizumab | CRL 2025-03-20: Jiangsu Hengrui Pharmaceuticals Co., Ltd BLA 761308 (camrelizumab) |
| 2025-03-20 | FDA approval | approved | NOVARTIS NVS | FABHALTA | Approved 2025-03-20: FABHALTA (NDA218276 SUPPL4) |
| 2025-03-20 | FDA approval | approved | ALNYLAM PHARMS INC ALNY | AMVUTTRA | Approved 2025-03-20: AMVUTTRA (NDA215515 SUPPL6) |
| 2025-03-20 | FDA approval | approved | JANSSEN BIOTECH | TREMFYA | Approved 2025-03-20: TREMFYA (BLA761061 SUPPL24) |
| 2025-03-20 | FDA approval | approved | TELIX INNOVATIONS TLX | GOZELLIX | Approved 2025-03-20: GOZELLIX (NDA219592 ORIG1) |
| 2025-03-21 | FDA approval | approved | JANSSEN PRODS | PREZCOBIX | Approved 2025-03-21: PREZCOBIX (NDA205395 SUPPL28) |
| 2025-03-25 | FDA approval | approved | FRESENIUS KABI USA LLC | BOMYNTRA; CONEXXENCE | Approved 2025-03-25: BOMYNTRA; CONEXXENCE (BLA761398 ORIG1) |
| 2025-03-25 | FDA approval | approved | GLAXOSMITHKLINE | BLUJEPA | Approved 2025-03-25: BLUJEPA (NDA218230 ORIG1) |
| 2025-03-26 | Complete response letter | complete response | CELLTRION, Inc. | CRL 2025-03-26: CELLTRION, Inc. BLA 761377 | |
| 2025-03-26 | FDA approval | approved | SOLENO | VYKAT XR | Approved 2025-03-26: VYKAT XR (NDA216665 ORIG1) |
| 2025-03-26 | FDA approval | approved | EXELIXIS INC EXEL | CABOMETYX | Approved 2025-03-26: CABOMETYX (NDA208692 SUPPL17) |
| 2025-03-27 | Complete response letter | complete response | Milestone Pharmaceuticals USA, Inc. MIST | etripamil nasal spray | CRL 2025-03-27: Milestone Pharmaceuticals USA, Inc. NDA 218571 (etripamil nasal spray) |
| 2025-03-27 | FDA approval | approved | NOVO NVO | RIVFLOZA | Approved 2025-03-27: RIVFLOZA (NDA215842 SUPPL2) |
| 2025-03-28 | FDA approval | approved | OTSUKA | ABILIFY ASIMTUFII | Approved 2025-03-28: ABILIFY ASIMTUFII (NDA217006 SUPPL1) |
| 2025-03-28 | FDA approval | approved | NOVARTIS NVS | PLUVICTO | Approved 2025-03-28: PLUVICTO (NDA215833 SUPPL21) |
| 2025-03-28 | FDA approval | approved | GENZYME CORP | QFITLIA | Approved 2025-03-28: QFITLIA (NDA219019 ORIG1) |
| 2025-03-28 | FDA approval | approved | ASTRAZENECA UK LTD AZN | IMFINZI | Approved 2025-03-28: IMFINZI (BLA761069 SUPPL50) |
| 2025-03-28 | FDA approval | approved | OTSUKA PHARM CO LTD | ABILIFY MAINTENA KIT | Approved 2025-03-28: ABILIFY MAINTENA KIT (NDA202971 SUPPL18) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-03 est. | P3 | SynCore Biotechnology Co., Ltd. | NCT03002103 A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line T | Triple-Negative Breast Cancer | suspended | 420 |
| 2025-03 est. | P2/P3 | 1Globe Health Institute LLC | NCT03721744 A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | Metastatic Pancreatic Cancer | unknown | 336 |
| 2025-03 est. | P2 | Imara, Inc. | NCT04053803 An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia | Sickle Cell Disease | active not recruiting | 30 |
| 2025-03 est. | P1/P2 | Philogen S.p.A. | NCT04573192 A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression | Glioblastoma | unknown | 142 |
| 2025-03 est. | P3 | Instituto Grifols, S.A. | NCT04636268 FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis | Congenital Afibrinogenemia; Hypofibrinogenemia | withdrawn | |
| 2025-03 est. | P1/P2 | JeniVision, Inc. | NCT04761705 Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension | Ocular Hypertension; Open Angle Glaucoma | suspended | 70 |
| 2025-03 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04780217 Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | Solid Tumor; Hepatocellular Carcinoma; Colorectal Cancer; NSCLC; Ovarian Cancer; Endometrial Cancer | unknown | 42 |
| 2025-03 est. | P3 | Beijing Mabworks Biotech Co., Ltd. | NCT04834024 MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma | Follicular Lymphoma and Marginal Zone Lymphoma | unknown | 168 |
| 2025-03 est. | P3 | Romark Laboratories L.C. | NCT05157269 Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness | COVID-19 | withdrawn | |
| 2025-03 est. | P1/P2 | 23andMe, Inc. | NCT05199272 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Solid Tumor; Clear Cell Renal Cell Carcinoma; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Prim | active not recruiting | 141 |
| 2025-03 est. | P1/P2 | Chipscreen Biosciences, Ltd. | NCT05271292 Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. | Small Cell Lung Cancer; Advanced Solid Malignant Tumor | unknown | 36 |
| 2025-03 est. | P2 | AmMax Bio, Inc. | NCT05349760 A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis | IPF | withdrawn | |
| 2025-03 est. | P3 | Hugel | NCT05801146 Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines | Glabellar Lines | unknown | 272 |
| 2025-03 est. | P2 | Immunoforge Co. Ltd. | NCT05833711 Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy | Dermatomyositis; Polymyositis; Idiopathic Inflammatory Myopathies | unknown | 39 |
| 2025-03 est. | P1/P2 | AsclepiX Therapeutics, Inc. | NCT05859776 Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | unknown | 15 |
| 2025-03 est. | P3 | Walvax Biotechnology Co., Ltd. | NCT05934890 A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 | Pneumococcal Disease, Invasive | unknown | 630 |
| 2025-03 est. | P3 | Cellid Co., Ltd. | NCT05993325 Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers | COVID-19; Vaccines | active not recruiting | 4000 |
| 2025-03 est. | P3 | Mabscale, LLC | NCT06005532 Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira® | Plaque Psoriasis | unknown | 494 |
| 2025-03 est. | P2 | Biocells (Beijing) Biotech Co.,Ltd | NCT06322394 BXOS110 Injection in the Treatment of Acute Ischaemic Stroke | Acute Ischemic Stroke | unknown | 300 |
| 2025-03 est. | P2/P3 | Equipmed USA LLC | NCT06602284 A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks. | Acne | unknown | 10 |
| 2025-03-01 | P3 | Pfizer PFE | NCT04607421 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Neoplasms | active not recruiting | 841 |
| 2025-03-01 est. | P3 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | NCT04736394 A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in | Non-muscle Invasive Bladder Cancer | unknown | 800 |
| 2025-03-01 est. | P1/P2 | Erasca, Inc. ERAS | NCT05279859 A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | Acute Myeloid Leukemia | withdrawn | |
| 2025-03-01 est. | P2/P3 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT05673512 To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer | HER2 Gene Mutation | unknown | 279 |
| 2025-03-01 | P3 | AbbVie ABBV | NCT05861427 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine | Migraine | completed | 524 |
| 2025-03-03 | P2 | ALX Oncology Inc. ALXO | NCT04675294 Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma | active not recruiting | 189 |
| 2025-03-03 | P2 | ALX Oncology Inc. ALXO | NCT04675333 Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma | active not recruiting | 172 |
| 2025-03-03 | P2 | Daiichi Sankyo | NCT05280470 Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Extensive-stage Small-cell Lung Cancer | active not recruiting | 187 |
| 2025-03-03 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05864014 Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. | Chemotherapy-Induced Thrombocytopenia | active not recruiting | 213 |
| 2025-03-03 | P2 | Kyoto Drug Discovery and Development Co., Ltd. | NCT06178055 A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) | Central Retinal Artery Occlusion | completed | 17 |
| 2025-03-03 | P2 | Causeway Therapeutics | NCT06192927 Efficacy and Safety of TenoMiR in Lateral Epicondylitis | Tennis Elbow | completed | 123 |
| 2025-03-04 | P1/P2 | Beijing Mabworks Biotech Co., Ltd. | NCT05398653 A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy | Primary Membranous Nephropathy | completed | 94 |
| 2025-03-04 est. | P1/P2 | Shanghai Henlius Biotech | NCT05641493 A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | Non Small Cell Lung Cancer | unknown | 49 |
| 2025-03-04 | P2 | Cognition Therapeutics CGTX | NCT05893537 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). | Age-Related Macular Degeneration | terminated | 100 |
| 2025-03-04 | P3 | Sarepta Therapeutics, Inc. SRPT | NCT06246513 A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrop | Limb-girdle Muscular Dystrophy | active not recruiting | 17 |
| 2025-03-04 | P2 | Gilgamesh Pharmaceuticals | NCT06309277 A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD | Major Depressive Disorder | completed | 46 |
| 2025-03-04 | P3 | Serum Institute of India Pvt. Ltd. | NCT06413121 Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV | Diptheria Immunization; Tetanus Immunization; Pertussis Immunization; Hepatitis B Immunization; Haem | completed | 1557 |
| 2025-03-04 | P2 | Scholar Rock, Inc. SRRK | NCT06445075 Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | Overweight and Obesity | completed | 102 |
| 2025-03-04 est. | P3 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | NCT06759857 FHND9041 Versus Afatinib for Non-small Cell Lung Cancer | Non Small Cell Lung Cancer | enrolling by invitation | 350 |
| 2025-03-05 | P2 | Hoffmann-La Roche | NCT04832854 A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participan | Non-Small Cell Lung Cancer (NSCLC) | terminated | 50 |
| 2025-03-05 | P3 | Merck Sharp & Dohme LLC MRK | NCT05116189 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | Ovarian Cancer; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms | active not recruiting | 643 |
| 2025-03-05 | P2 | Sanofi SNY | NCT05326412 Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD | Chronic Obstructive Pulmonary Disease | completed | 49 |
| 2025-03-05 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05472324 Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. | Severe Asthma | completed | 205 |
| 2025-03-05 | P2 | Pfizer PFE | NCT05492500 A Study of Ponsegromab in People With Heart Failure | Heart Failure | terminated | 455 |
| 2025-03-05 | P3 | Novo Nordisk A/S NVO | NCT05514535 A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People Wit | Diabetes Mellitus, Type 2; Obesity | completed | 573 |
| 2025-03-05 | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05913336 A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU | Sedation in the ICU | completed | 24 |
| 2025-03-05 | P2 | Keros Therapeutics, Inc. KROS | NCT05975905 A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH | Pulmonary Arterial Hypertension | terminated | 113 |
| 2025-03-05 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06221059 Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease | Chronic Kidney Disease | completed | 181 |
| 2025-03-05 | P2 | Sinotau Pharmaceutical Group | NCT07187895 Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis | Myocardial Perfusion Imaging; Diagnostic Certainty; Stable Coronary Artery Disease | terminated | 17 |
| 2025-03-05 | P2 | Novartis Pharmaceuticals NVS | NCT07235033 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) | Uncomplicated Plasmodium Falciparum Malaria | completed | 60 |
| 2025-03-06 | P2/P3 | Magnus Medical | NCT03693105 The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition | Major Depressive Disorder; Major Depressive Episode; Suicidal Ideation | terminated | 2 |
| 2025-03-06 est. | P2 | Hoffmann-La Roche | NCT04611776 A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Com | Carcinoma, Non-Small Cell Lung | withdrawn | |
| 2025-03-06 | P1/P2 | Affimed GmbH | NCT05109442 Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Advanced Solid Tumor | terminated | 112 |
| 2025-03-06 | P3 | Bristol-Myers Squibb BMY | NCT05582395 A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | terminated | 580 |
| 2025-03-06 | P3 | Novartis Pharmaceuticals NVS | NCT05678959 Long-term Extension Study of Ligelizumab in Food Allergy | Food Allergy | terminated | 163 |
| 2025-03-06 | P2 | iRenix Medical, Inc. | NCT05747430 SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) | Retinal Disease | completed | 155 |
| 2025-03-06 | P2 | Incyte Corporation INCY | NCT05750823 A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | Nonsegmental Vitiligo With Genital Involvement | completed | 49 |
| 2025-03-06 | P2 | Avistone Biotechnology Co., Ltd. | NCT06015503 A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) | NSCLC (Non-small Cell Lung Cancer) | active not recruiting | 139 |
| 2025-03-06 | P2 | Tourmaline Bio, Inc., a Novartis Company | NCT06362759 A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP | Chronic Kidney Diseases; Chronic Kidney Insufficiency; Chronic Renal Diseases; Chronic Renal Insuffi | completed | 143 |
| 2025-03-06 | P2/P3 | Magnus Medical | NCT06462820 SAINT for MDD in an Inpatient Setting Follow-on | Major Depressive Disorder; Major Depressive Episode; Suicidal Ideation | terminated | 2 |
| 2025-03-06 | P2 | Kiniksa Pharmaceuticals International, plc KNSA | NCT06531395 A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease | Sjögrens Disease | terminated | 3 |
| 2025-03-07 | P1/P2 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | NCT04535193 Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation | Cardiovascular Diseases | active not recruiting | 10 |
| 2025-03-07 | P2 | BioTissue Holdings, Inc | NCT05079035 Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA | Knee Osteoarthritis; Knee Pain Chronic; Knee Arthritis | completed | 90 |
| 2025-03-07 | P2 | SOFIE | NCT05262855 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma | PDAC - Pancreatic Ductal Adenocarcinoma; FAP | completed | 63 |
| 2025-03-07 | P3 | Bristol-Myers Squibb BMY | NCT05644665 A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Ulcerative Colitis | terminated | 131 |
| 2025-03-07 | P1/P2 | Imunon IMNN | NCT06283459 Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 | SARS CoV 2 Infection | completed | 24 |
| 2025-03-07 | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06901648 A Study of HS-20094 in Patients With T2DM | Type 2 Diabetes | completed | 275 |
| 2025-03-07 | P2 | Accro Bioscience (Suzhou) Limited | NCT06972888 A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis | Plaque Psoriasis | completed | 145 |
| 2025-03-08 | P2 | Technoderma Medicines Inc. | NCT06363461 Study of TDM-180935 in Atopic Dermatitis Patients | Atopic Dermatitis | completed | 24 |
| 2025-03-10 | P3 | Apnimed APMD | NCT05813275 Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) | OSA | completed | 646 |
| 2025-03-10 | P3 | GlaxoSmithKline | NCT06597344 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Uri | Urinary Tract Infections | completed | 97 |
| 2025-03-11 | P3 | AGO Research GmbH | NCT03353831 Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | Recurrent Ovarian Carcinoma | completed | 574 |
| 2025-03-11 | P1/P2 | Astellas Pharma Global Development, Inc. | NCT04240002 A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Du | Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | terminated | 9 |
| 2025-03-11 | P2/P3 | Galectin Therapeutics Inc. GALT | NCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis | Prevention of Esophageal Varices; NASH - Nonalcoholic Steatohepatitis; Cirrhosis | terminated | 357 |
| 2025-03-11 | P1/P2 | Neurelis, Inc. | NCT05076838 Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy | Epilepsy | completed | 36 |
| 2025-03-11 | P2 | Novartis Pharmaceuticals NVS | NCT05432388 Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts | Allergy, Peanut | completed | 76 |
| 2025-03-11 | P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06251024 Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older | Respiratory Syncytial Virus Infection; Healthy Volunteers | completed | 4541 |
| 2025-03-12 | P2 | UCB Biopharma SRL | NCT04718896 A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psorias | Moderate to Severe Plaque Psoriasis | completed | 41 |
| 2025-03-12 | P3 | AstraZeneca AZN | NCT05113251 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | Breast Neoplasms; Breast Cancer; HER2-positive Early Breast Cancer | active not recruiting | 927 |
| 2025-03-13 | P2 | Arbutus Biopharma Corporation ABUS | NCT04980482 Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | Chronic Hepatitis b | completed | 43 |
| 2025-03-13 | P1/P2 | Astria Therapeutics, Inc. | NCT05695248 A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema | Hereditary Angioedema | completed | 29 |
| 2025-03-13 | P3 | Sintetica SA | NCT05926258 Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population | Local Anesthetic | completed | 74 |
| 2025-03-13 | P2/P3 | BioNTech SE BNTX | NCT05997290 A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals | SARS-CoV-2 Infection; COVID-19 | completed | 1051 |
| 2025-03-13 | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06572449 Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia | Schizophrenia | completed | 173 |
| 2025-03-13 | P2 | Aclaris Therapeutics, Inc. ACRS | NCT06585202 Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | completed | 14 |
| 2025-03-14 est. | P1/P2 | Shanghai EpimAb Biotherapeutics Co., Ltd. | NCT03797391 A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | Neoplasms; Neoplasm Metastasis; Non-Small-Cell Lung Cancer | unknown | 186 |
| 2025-03-14 | P2 | Bayer | NCT05254002 A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participa | Type 2 Diabetes Mellitus; Chronic Kidney Disease | completed | 1664 |
| 2025-03-14 | P2 | Incyte Biosciences International Sàrl INCY | NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastati | Head and Neck Cancer | completed | 176 |
| 2025-03-14 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05476900 A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. | Autoimmune Hepatitis | completed | 69 |
| 2025-03-14 | P2 | Regend Therapeutics | NCT06081621 A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | completed | 23 |
| 2025-03-14 est. | P2 | Jemincare | NCT06221241 Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | unknown | 220 |
| 2025-03-14 | P2 | Estetra | NCT06308614 Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women | Sexual Dysfunction, Physiological | completed | 82 |
| 2025-03-14 | P3 | Huons Co., Ltd. | NCT06388070 To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome | Dry Eye Syndromes | completed | 297 |
| 2025-03-15 est. | P2 | Energenesis Biomedical Co., Ltd. | NCT04078555 A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer | Venous Leg Ulcer | unknown | 80 |
| 2025-03-15 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05261646 A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Th | Chemotherapy-Induced Thrombocytopenia | withdrawn | |
| 2025-03-15 est. | P2 | Tavotek Biotherapeutics | NCT06176040 A Study of TAVO101 in Atopic Dermatitis Patients | Atopic Dermatitis | active not recruiting | 20 |
| 2025-03-15 est. | P3 | EMS | NCT06237231 Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third Molars | Moderate Pain; Severe Pain | not yet recruiting | 252 |
| 2025-03-15 est. | P3 | EMS | NCT06272409 Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children. | Allergic Rhinitis | not yet recruiting | 318 |
| 2025-03-15 est. | P1/P2 | MGB Pharma | NCT06672653 Tolerance and Effectiveness of C14 on HPV Infection | HPV-induced Cancers; HPV Infections; HIV; Cervical Cancers; Trial; C14; Monoterpenoid Zinc Tetra-asc | not yet recruiting | 66 |
| 2025-03-17 | P3 | AstraZeneca AZN | NCT03737643 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovaria | Advanced Ovarian Cancer | active not recruiting | 1407 |
| 2025-03-17 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05428033 A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) | Attention Deficit/Hyperactivity Disorder | completed | 574 |
| 2025-03-17 | P2/P3 | Nicox Ophthalmics, Inc. | NCT05938699 Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution | Open Angle Glaucoma | completed | 18 |
| 2025-03-18 | P1/P2 | Janssen Research & Development, LLC | NCT04586426 A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | active not recruiting | 228 |
| 2025-03-18 | P3 | UCB Biopharma SRL | NCT05109234 A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Ju | Childhood Absence Epilepsy; Juvenile Absence Epilepsy | completed | 84 |
| 2025-03-18 | P3 | Vascular Therapies, Inc. | NCT05425056 A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery | Complication of Renal Dialysis; End Stage Renal Disease; End Stage Kidney Disease; ESRD; Chronic Kid | completed | 136 |
| 2025-03-18 | P2 | Dompé Farmaceutici S.p.A | NCT05496868 Add-on Reparixin in Adult Patients With ARDS | Acute Respiratory Distress Syndrome, Adult | completed | 66 |
| 2025-03-18 | P2 | UCB Biopharma SRL | NCT05543252 An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease | Parkinson's Disease | terminated | 428 |
| 2025-03-18 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT05774756 A Trial of Setmelanotide in Acquired Hypothalamic Obesity | Hypothalamic Obesity | active not recruiting | 143 |
| 2025-03-18 | P2 | NorthSea Therapeutics B.V. | NCT05889156 Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia | High Triglycerides | completed | 50 |
| 2025-03-19 | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT05145413 A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Schizophrenia | completed | 396 |
| 2025-03-19 | P1/P2 | BioAtla, Inc. BCAB | NCT05180799 A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | NSCLC; Melanoma | unknown | 320 |
| 2025-03-19 | P1/P2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT05197842 Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis | ANCA-associated Vasculitis | completed | 93 |
| 2025-03-19 | P2/P3 | Ipsen | NCT05769582 Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients | BK Viremia; BKV DNAemia | completed | 95 |
| 2025-03-19 | P3 | Materia Medica Holding | NCT06263881 Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia | Community-acquired Pneumonia; Pneumonia | completed | 370 |
| 2025-03-20 | P3 | Merck Sharp & Dohme LLC MRK | NCT03867084 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological | Hepatocellular Carcinoma | completed | 959 |
| 2025-03-20 | P3 | AstraZeneca AZN | NCT04609904 Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) | Asthma | completed | 2187 |
| 2025-03-20 | P3 | Liquidia Technologies, Inc. LQDA | NCT04691154 A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | Pulmonary Arterial Hypertension; Pulmonary Hypertension Due to Lung Diseases | active not recruiting | 28 |
| 2025-03-20 | P3 | argenx ARGX | NCT05681481 A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Bullous Pemphigoid | terminated | 64 |
| 2025-03-20 | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05774873 The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 | Advanced Solid Tumors | completed | 28 |
| 2025-03-20 | P2 | Carrick Therapeutics Limited | NCT05963984 A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer | completed | 60 |
| 2025-03-20 | P1/P2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT06038916 To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome | completed | 47 |
| 2025-03-20 | P2 | Merck Sharp & Dohme LLC MRK | NCT06113328 A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) | Non-segmental Vitiligo | terminated | 169 |
| 2025-03-21 | P2 | Bristol-Myers Squibb BMY | NCT03920267 Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 261 |
| 2025-03-21 | P3 | AstraZeneca AZN | NCT04609878 Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) | Asthma | completed | 2274 |
| 2025-03-21 | P3 | EMD Serono Research & Development Institute, Inc. | NCT05061823 Bintrafusp Alfa Program Rollover Study | Lung Cancer; Cancer | completed | 22 |
| 2025-03-21 | P3 | Spine BioPharma, Inc | NCT05516992 Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine | Lumbar Degenerative Disc Disease | active not recruiting | 417 |
| 2025-03-21 | P3 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | NCT06209320 A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops | Myopia | active not recruiting | 777 |
| 2025-03-21 | P3 | Alcon Research ALC | NCT06544694 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease | Dry Eye Disease | completed | 80 |
| 2025-03-22 | P1/P2 | Xilio Development, Inc. XLO | NCT05052268 XTX202 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | completed | 95 |
| 2025-03-22 | P1/P2 | Lubris Bio Pty Ltd | NCT06495307 RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) | Ocular Graft-versus-host Disease | terminated | 3 |
| 2025-03-23 | P3 | Eurofarma Laboratorios S.A. | NCT05214911 Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children | Allergic Rhinitis | completed | 262 |
| 2025-03-23 | P1/P2 | Altesa Biosciences, Inc. | NCT06834295 A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir | Healthy Males | completed | 8 |
| 2025-03-24 | P2/P3 | Gilead Sciences GILD | NCT02881320 Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 | HIV-1 Infection | active not recruiting | 177 |
| 2025-03-24 | P3 | BioTissue Holdings, Inc | NCT04450693 Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) | Diabetic Foot Infection; Non-healing Wound; Non-healing Diabetic Foot Ulcer | completed | 106 |
| 2025-03-24 | P3 | AstraZeneca AZN | NCT05398263 Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma | Asthma | terminated | 125 |
| 2025-03-24 | P2 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | NCT05558696 A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) | Polycythemia Vera | completed | 20 |
| 2025-03-24 | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06603623 Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine | Migraine | completed | 647 |
| 2025-03-25 | P2 | Sarfez Pharmaceuticals, Inc. | NCT06176794 Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal | Heart Failure | withdrawn | |
| 2025-03-25 | P2 | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | NCT07319351 Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome (ARDS) | completed | 57 |
| 2025-03-25 | P1/P2 | BioNanoSim Ltd. | NCT07869953 Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis | Non-Infectious Anterior Uveitis | completed | 18 |
| 2025-03-26 | P2 | Agenus Inc. AGEN | NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Cervical Cancer | terminated | 211 |
| 2025-03-26 | P3 | Sun Pharmaceutical Industries Limited | NCT04314544 Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | Active Psoriatic Arthritis | completed | 508 |
| 2025-03-26 | P2 | Alexion Pharmaceuticals, Inc. | NCT04564339 Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | Lupus Nephritis; Immunoglobulin A Nephropathy | terminated | 123 |
| 2025-03-26 | P2 | Novartis Pharmaceuticals NVS | NCT05524051 A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. | Acute Kidney Injury Following Cardiac Surgery | terminated | 102 |
| 2025-03-26 | P3 | Amgen AMGN | NCT05907122 A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | Melanoma | completed | 256 |
| 2025-03-26 | P2 | Apollo Therapeutics Ltd APO | NCT06436183 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis; Atopic; Dermatitis; Dermatologic Disease; Eczema; Eczema Atopic Dermatitis; Eczem | completed | 62 |
| 2025-03-27 | P2 | Insmed Incorporated INSM | NCT05147805 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | completed | 102 |
| 2025-03-27 | P2 | GCP-Service International West GmbH | NCT05583552 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy | Myelodysplastic Syndromes; Acute Myeloid Leukemia | completed | 46 |
| 2025-03-27 | P3 | Addpharma Inc. | NCT06052748 A Study to Evaluate the Efficacy and Safety of AD-223 | Hypertension,Essential | completed | 502 |
| 2025-03-27 | P3 | Laboratorios Liomont | NCT07549386 Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis. | Pain Management; Osteoarthritis | completed | 123 |
| 2025-03-28 | P2 | Theriva Biologics SL TOVX | NCT05673811 Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma; Metastatic | completed | 112 |
| 2025-03-28 | P2 | Beckley Psytech Limited | NCT05870540 BPL-003 Efficacy and Safety in Treatment Resistant Depression | Treatment Resistant Depression | completed | 196 |
| 2025-03-28 | P2 | Ascendis Pharma A/S ASND | NCT05980598 TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms | terminated | 27 |
| 2025-03-28 | P2 | Amgen AMGN | NCT06502977 Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment | Extensive Stage Small Cell Lung Cancer | active not recruiting | 32 |
| 2025-03-28 | P3 | Yuhan Corporation | NCT06625931 Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition | Parenteral Nutrition | completed | 60 |
| 2025-03-28 | P3 | SPH-BIOCAD (HK) Limited | NCT07008547 To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 202 |
| 2025-03-30 | P1/P2 | Vascudyne, Inc. | NCT05567757 Initial Safety Study of the TRUE AVC in Hemodialysis Access (TRUE AVC I Study) | End Stage Renal Disease | completed | 11 |
| 2025-03-30 | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06089278 A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. | Sinusitis | completed | 160 |
| 2025-03-30 | P2 | Altesa Biosciences, Inc. | NCT06149494 RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection | COPD Exacerbation Acute; COPD With Acute Lower Respiratory Infection; Rhinovirus; Virus Diseases; Vi | completed | 52 |
| 2025-03-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT06171074 Study of CM310 in Subjects With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | unknown | 100 |
| 2025-03-30 est. | P2 | Jubaan Ltd. | NCT06612281 Evaluation of Gixam's Performance in a FIT Negative Population | Colorectal Adenoma; Colorectal Cancer (CRC); Colorectal Cancer (CRC) Screening | recruiting | 400 |
| 2025-03-31 | P2 | Astellas Pharma Global Development, Inc. | NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) | Stargardt's Macular Dystrophy | completed | 121 |
| 2025-03-31 | P2 | Regeneron Pharmaceuticals REGN | NCT03916627 Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | Non-small Cell Lung Cancer; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma | active not recruiting | 65 |
| 2025-03-31 | P2 | Leap Therapeutics, Inc. | NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | Gastric Cancer; Gastric Adenocarcinoma; GastroEsophageal Cancer | terminated | 247 |
| 2025-03-31 | P2 | Mirror Biologics, Inc. | NCT04444622 Immunotherapy for Third Line Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | completed | 29 |
| 2025-03-31 est. | P3 | Allerderm | NCT04500834 Metal Panel Allergen Patch Test Study | Atopic Dermatitis Eczema | unknown | 200 |
| 2025-03-31 est. | P3 | Zogenix MDS, Inc. | NCT04581733 A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) | Thymidine Kinase 2 Deficiency | withdrawn | |
| 2025-03-31 | P2 | Dompé Farmaceutici S.p.A | NCT04628481 A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function | Recent Onset type1 Diabetes | terminated | 289 |
| 2025-03-31 | P1/P2 | MegaPro Biomedical Co. Ltd. | NCT04643418 Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | Solid Tumor, Unspecified, Adult | recruiting | 81 |
| 2025-03-31 | P3 | Opthea Limited CKDXF | NCT04757610 OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | terminated | 986 |
| 2025-03-31 | P3 | Opthea Limited CKDXF | NCT04757636 OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | terminated | 998 |
| 2025-03-31 | P2 | BeiGene | NCT05068440 Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma | completed | 65 |
| 2025-03-31 | P2 | GlaxoSmithKline | NCT05082285 A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants | Infections, Meningococcal | completed | 726 |
| 2025-03-31 | P3 | Corcept Therapeutics CORT | NCT05257408 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms | active not recruiting | 381 |
| 2025-03-31 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05435248 Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | Advanced or Metastatic NSCLC | unknown | 354 |
| 2025-03-31 | P2 | HighTide Therapeutics (Hong Kong) Limited | NCT05623189 HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes | Nonalcoholic Steatohepatitis (NASH); Type 2 Diabetes | completed | 218 |
| 2025-03-31 | P2 | AbbVie ABBV | NCT05941442 A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | Panic Disorder | terminated | 80 |
| 2025-03-31 | P2 | UCB Biopharma SRL | NCT06055985 A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease | Parkinson Disease | completed | 207 |
| 2025-03-31 | P2 | Shionogi | NCT06086626 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants | Gram-Negative Bacterial Infections | completed | 30 |
| 2025-03-31 | P3 | Dermata Therapeutics DRMA | NCT06090721 DMT310-009 Topical in the Treatment of Acne Vulgaris | Acne Vulgaris | completed | 520 |
| 2025-03-31 est. | P2 | Evon Medics LLC | NCT06434818 Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders | Substance Use Disorders; Opioid Use Disorder; Alcohol Use Disorder; Cocaine Use Disorder; Methamphet | unknown | 300 |
| 2025-03-31 | P2 | Dizal Pharmaceuticals | NCT06511869 AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | Peripheral T-cell Lymphoma | completed | 48 |
| 2025-03-31 est. | P2 | Acousia Therapeutics GmbH | NCT06521190 ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin | Cisplatin-induced Hearing Loss | unknown | 40 |
| 2025-03-31 est. | P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06642961 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to | Asthma | unknown | 150 |
| 2025-03-31 est. | P2 | Hyundai Pharm | NCT06647550 To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise | Type 2 Diabetes Mellitus (T2DM) | recruiting | 160 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.